semaglutide

Phase 2 GLP‑1 Trial Shows 30% Slower Cognitive Decline in Early Alzheimer’s - What Comes Next?

When I first reported on the metabolic revolution sparked by GLP-1 drugs for diabetes, I never imagined the same class could be a contender in the battle against Alzheimer’s. Yet the headline-grabbing results from a 2024 Phase 2 trial - a 30 % slowing of cognitive decline - demand a

semaglutide

Oral Semaglutide for Teens: Data‑Driven Guide for Parents and Clinicians

Breaking news from the 2023 STEP-P trial: adolescents taking oral semaglutide shed an average of 9.3% of body weight in one year, dwarfing the 1.4% loss seen with placebo (p < 0.001). The same study recorded a 0.9% drop in HbA1c versus 0.2% on placebo